Related Experiment Video
Updated: Aug 2, 2026

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
Published on: August 11, 2015
Switching to amisulpride monotherapy for treatment-resistant schizophrenia
V P Kontaxakis1, B J Havaki-Kontaxaki, P P Ferentinos
1Department of Psychiatry, University of Athens, Eginition Hospital, 74 Vas. Sophias Avenue, 11528 Athens, Greece. bkont@cc.uoa.gr
Abstract:
The objective of this study was to assess switching to amisulpride (AMS) in treatment-resistant schizophrenia. Seven male subjects were switched to AMS and followed for 8 weeks. PANSS scores improved from 123 to 66 over this period. We conclude that AMS is of interest in the treatment of refractory schizophrenia.
Related Concept Videos
Psychosis and Antipsychotic Drugs: Overview
Psychosis: Goals of Pharmacotherapy
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Antidepressant Drugs: MAOIs and Other Agents
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Drug Therapy
Antianxiety Medications

